



"Dementia: A Comprehensive Review of Pathophysiology, Diagnosis, And Management"

T. Vinciya¹, P. Prem Kumar*², D. Saravana Priya³, S.Thanga Ashwini⁴, R.Rajamini⁵, P. Senthil Kumar⁶

^{1,4,5}Department of Pharmacology, Faculty of Pharmacy, Dr. M.G.R Educational and Research Institute, Chennai-600077

⁶Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Dr. M.G.R Educational and Research Institute, Chennai-600077.

^{2,3}Department of Pharmaceutics, Saveetha College of Pharmacy, Thandalam, Chennai-600077

*Corresponding Author: P. Prem Kumar.,

(Received: 16 May 2025

Revised: 20 June 2025

Accepted: 02 July 2025)

KEYWORDS

Dementia,
Alzheimer's
disease,

Neurodegener
ative
disorders,

Cognitive
decline,

Amyloid-beta
plaques,

Neurofibrillar
tangles

ABSTRACT:

Introduction:

Dementia is a progressive neurodegenerative disorder marked by a decline in memory, cognition, and behavioral functioning, ultimately leading to loss of independence. With Alzheimer's disease being the most prevalent form, dementia presents in various subtypes, each with distinct clinical and pathological features.

Objectives:

This review aims to comprehensively explore the types of dementia, elucidate the underlying pathophysiology, identify key risk factors, examine current diagnostic and therapeutic strategies, and highlight future directions in research and management.

Methods:

An extensive literature review was conducted using peer-reviewed articles, clinical guidelines, and epidemiological studies related to dementia. Data were analyzed to identify trends in disease prevalence, diagnostic advancements, and therapeutic approaches.

Results:

Alzheimer's disease accounts for 60–80% of dementia cases, characterized by amyloid-beta plaques and neurofibrillary tangles. Other forms include vascular dementia, Lewy body dementia, and frontotemporal dementia. Major risk factors include aging, cardiovascular conditions, depression, genetic mutations, and environmental influences. Advances in biomarkers, neuroimaging, and molecular diagnostics have enhanced early detection, though diagnostic challenges remain. Current pharmacological treatments provide symptomatic relief but fail to halt disease progression. Non-pharmacological interventions and caregiver support significantly improve patient quality of life.

Conclusion:

The global burden of dementia is escalating, with cases projected to surpass 130 million by 2050. Tackling this public health crisis requires early diagnosis, integrated care, supportive policies, and sustained research into disease-modifying therapies. Future breakthroughs in diagnostics and treatment offer hope for improved outcomes and quality of life for patients and caregivers alike.

1. Introduction

Progressive cognitive decline and neuropsychiatric symptoms are hallmarks of dementia, a syndrome that is most frequently caused by Alzheimer's disease (AD), which accounts for 60–80% of cases [1]. An estimated

24 million people worldwide suffer from dementia, and until 2040, this number is predicted to grow every 20 years. The neuropathological features of the AD brain include intracellular neurofibrillary tangles and widespread and neuritic extracellular amyloid plaques,



which are often encircled by dystrophic neurites. These characteristic diseases are frequently accompanied by reactive microgliosis and the death of synapses, neurons, and white matter [2]. Lewy body dementia, the dementia-Parkinson complex, frontotemporal dementia, and vascular dementia are examples of neurodegenerative dementias. The prevalence of other dementia subtypes is less than 1%, and the epidemiological markers that are now available are not very reliable [3]. Dementia patients often live for seven to ten years after their symptoms start. Dementia is one of the biggest problems of this century and imposes a great strain on society as well as on caretakers [4]. Although there isn't a cure or disease-modifying treatment for dementia at this time, improved policies can help those who have the illness, and their families cope with it and make sure they have access to high-quality social and health care [1].

"The Global Burden of Dementia: Prevalence, Incidence, and Impact"


With an expected 51.6 million afflicted globally in 2019 (5), the burden of dementia is rising quickly. In sub-Saharan Africa, prevalence rates range from 2–4%, while in Latin America, they range from 8.5% (6). Prevalence rates are often greater in high-income nations; Japan leads the pack with 3,079 cases per 100,000 (5). Dementia is expected to affect 75.62 million individuals in 2030 and 135.46 million in 2050, roughly doubling every 20 years (7). In low- and middle-income nations, where 58% of dementia cases were reported in 2010, this trend is anticipated to climb to 71% by 2050. With worldwide expenses estimated at US \$818 billion in 2015 and expected to reach US \$1 trillion by 2018, the economic impact is significant(6).

Pathophysiology of dementia

Cognitive decline and behavioral abnormalities are hallmarks of dementia, especially Alzheimer's disease (AD), a complicated neurological disorder (8). Cerebrovascular disease and protein aggregation, including amyloid- β plaques and neurofibrillary tangles, are part of the pathogenesis (9). Although the precise triggers are yet unknown, the amyloid cascade hypothesis postulates that aberrant amyloid- β synthesis starts secondary events (10). Cholinergic dysfunction, changes in glutamatergic neurotransmission, anomalies in tau proteins, oxidative stress, and calcium dysregulation are other important pathways (11). Memory problems and other cognitive impairments are caused by these processes, which also cause neuronal


death and damage. The clinical picture of dementia in older adults is complicated by the prevalence of mixed neuropathologies (9). Developing efficient diagnostic methods and therapies for dementia, especially AD, requires an understanding of these fundamental mechanisms.

PATHOPHYSIOLOGY OF DEMENTIA



Risk Factors for Dementia:

Several important risk factors for dementia are identified by meta-analyses and systematic reviews. Risk factors for cardiovascular disease, such as diabetes mellitus, dyslipidemia, and hypertension, are linked to an increased risk of dementia (12). There is strong evidence linking type 2 diabetes to vascular dementia and Alzheimer's disease. Dementia risk is also highly associated with depression, especially in later life, and decreased social interaction frequency (13). Although more thorough longitudinal studies are required, environmental factors like air pollution, pesticide exposure, and vitamin D insufficiency may increase the incidence of dementia (14). Most of the data comes from cardiovascular research, but the quality and geographic representativeness of the evidence vary depending on the risk variables. While not all relationships can be proven to be causal, controlling modifiable risk factors, particularly cardiovascular risks, may help prevent dementia and cognitive decline(12).



The Role of Genetics in Dementia :

Age-related dementias, especially frontotemporal dementia (FTD) and Alzheimer's disease (AD), are significantly influenced by genetics. While genome-wide association studies have found other risk genes, family forms of AD are associated with mutations in the APP, PSEN1, and PSEN2 genes. Mutations in the MAPT, GRN, VCP, CHMP2B, TARBDP, FUS, and C9orf72 genes are linked to FTD (15). Most instances are caused by intricate combinations between genetic and environmental variables, however others have a definite genetic etiology with autosomal dominant inheritance. Those with a family history have a higher lifetime risk of dementia (20%) than the general population (10%)(16). By modifying gene expression without modifying DNA sequences, epigenetic processes such as DNA methylation, non-coding RNAs, and chromatin remodeling also contribute to the pathophysiology of AD and FTD(17).

The Clinical Spectrum of Dementia:

Mild cognitive impairment (MCI) and severe phases are at opposite ends of the clinical continuum of dementia. Many studies concentrate on early to moderate dementia, however people with severe dementia maintain environmental interactions and display individual distinctions rather than being in a "vegetative state". Cognitive and behavioral state in advanced dementia can be measured using assessment instruments such as the Severe Impairment Battery and the Hierarchic Dementia Scale(18). Even in very moderately impaired people who don't quite fulfill MCI criteria, the degree of cognitive impairment in day-to-day functioning and neuropsychological test performance can predict the chance of an AD diagnosis within five years(19). Numerous prognostic factors influence the progression from MCI to dementia, and neuropsychological profiles are important in forecasting results(20). Correlating clinical data with findings from neuroimaging, neurochemistry, and

neuropathology requires an understanding of the full spectrum of dementia(18).

Diagnostic Approaches for Dementia:

Dementia diagnostic techniques have changed dramatically, incorporating a range of instruments and techniques. Current methods include biomarker analysis, neuroimaging, cognitive testing, and thorough clinical examinations. Using history taking, physical examinations, and cognitive tests, primary care physicians are essential in early diagnosis (21). Although there are obstacles to their practical implementation, cutting-edge methods like PET neuroimaging, genetics, and proteomics are being included in updated diagnostic criteria(22). Although biomarkers can increase the accuracy of diagnosing Alzheimer's disease, a comprehensive clinical evaluation is still necessary(23). New spectroscopic methods that show promise for dementia detection and monitoring include Raman and infrared spectroscopy. Despite these developments, dementia is still difficult to diagnose because of its variable symptoms, overlapping conditions, and potential for many etiologies, especially in elderly people(22).

Challenges in Diagnosing Dementia:

There are many difficulties in diagnosing dementia,

- Early and precise diagnosis is crucial for effective therapy(24)
- Symptoms vary and overlap with other illnesses, hindering diagnosis(22).
- Dementias like Alzheimer's and frontotemporal dementias pose diagnostic challenges(25)

Diagnostic skills have been enhanced by recent developments in biomarker research, such as proteomics, genomics, and neuroimaging. However, to improve biomarker analysis's consistency and dependability, global initiatives and method standardization are required. Although the integration of novel technologies such as PET scanning and biomarkers into updated diagnostic criteria exhibits potential, its clinical implementation is hindered by accessibility and availability issues (26). Research is still being conducted to improve diagnostic methods and get over these obstacles in dementia diagnosis.



Types of Dementia

Multiple underlying reasons contribute to dementia, a degenerative cognitive illness. The four most prevalent kinds are

TYPE1: Alzheimer's Disease

CHARACTERISTICS:

- Progressive neurological illness.
- defined by the buildup of neurofibrillary tangles and amyloid plaques in the brain.
- causes a slow deterioration in behavior, memory, and cognitive function.
- Memory loss, especially of recent events, is a common early sign.
- Later phases include issues with executive processes, language, and spatial awareness.

PATHOLOGY: Neurofibrillary tangles (abnormalities of tau proteins) and amyloid plaques (clumps of beta-amyloid proteins).

SYMPTOMS: Personality changes, language difficulties, disorientation, confusion, and memory loss.(27)

TYPE2: Vascular Dementia

CHARACTERISTICS:

- Caused by diminished blood supply to the brain because of cerebrovascular disorders, stroke, or transient ischemic attacks (TIAs).
- The location and degree of brain injury can affect the symptoms.
- May show up as a sharp or gradual loss in cognitive function.
- Frequently linked to other vascular risk factors, including diabetes, heart disease, and high blood pressure.

PATHOLOGY: Brain tissue damage brought on by a shortage of blood flow.

SYMPTOMS: Diminished judgment, Trouble organizing and planning, and issues focusing. Depending on where the strokes occurred, bodily symptoms may also be present.(28)

TYPE3: Lewy Body Dementia

CHARACTERISTICS:

- Distinguished by the brain's aberrant protein deposits, or Lewy bodies.

- Visual hallucinations, altered cognition, and parkinsonian symptoms (such as tremors and rigidity) are distinctive clinical characteristics.

- Frequently misidentified as Parkinson's or Alzheimer's disease.

- One prevalent early sign is REM sleep behavior disorder.

PATHOLOGY: Alpha-synuclein protein aggregates, or Lewy bodies, are seen in brain cells.

SYMPTOMS: Sleep problems, parkinsonian symptoms, Variations in alertness and attention, and Visual hallucinations.(29)

TYPE4: Frontotemporal Dementia

CHARACTERISTICS:

- Impacts the brain's frontal and temporal lobes, which oversee language, behavior, and personality.
- Exhibits noticeable alterations in language, conduct, and/or personality.
- Primary progressive aphasia (PPA) and behavioral variation frontotemporal dementia (bvFTD) are subtypes.
- Usually manifests earlier than Alzheimer's.

PATHOLOGY: Several protein anomalies, such as tau, TDP-43, and FUS.

SYMPTOMS: Alterations in behavior and personality (impulsivity, apathy), linguistic difficulties (word-finding issues, for example), and a reduction in executive functioning.(30)

Current Treatment Options for Dementia:

Pharmacological and non-pharmacological therapies are currently available as dementia therapy alternatives.

1. Non-pharmacological methods:

- Behavioral therapy.
- Sensory stimulation.
- Cognitive and emotion-oriented interventions are advised.
- Music therapy and therapies based on functional analysis have demonstrated notable benefits in the behavioral and psychological symptoms of dementia (BPSD).(31)



2. pharmacological methods

- Cholinesterase inhibitors like donepezil and galantamine.
- Both analgesics and antipsychotics may help control BPSD,
- Antipsychotics should be taken with caution because of their side effects. (32)

The origin, symptom profile, and stage of dementia all influence treatment strategies. Although dementia cannot be cured, these treatments try to reduce symptoms, delay the disease's progression, and enhance quality of life.

Cognitive Training and Rehabilitation for Dementia:

Interventions for cognitive abnormalities in people with mild to moderate Alzheimer's disease and vascular dementia include cognitive training (CT) and cognitive rehabilitation (CR). The total body of evidence supporting CT is still small and of low to intermediate quality, despite certain studies suggesting possible advantages. The meta-analysis found no differences between the control conditions and cognitive training on any of the primary or secondary results that were analyzed. Because the measures employed for each outcome varied, most comparisons were made using the standardized mean difference approach. Standardized mean differences between cognitive training and control conditions varied from -0.11 to 0.31, depending on the analysis. Additionally, it was generally agreed that the evidence from cognitive training programs up to this point was of poor to intermediate quality.

None of the included studies evaluated longer-term outcomes associated with the trajectory of dementia, such as dementia severity and rates of admission to residential care. (33)

Results from CT have been conflicting; some studies have found that it improves global cognition and training-specific skills, especially when used in more rigorous programs. There isn't much proof of better day-to-day functioning, though. Despite being less researched, CR has produced encouraging initial findings in one high-caliber RCT (34). Numerous trials may have produced exaggerated positive results due to methodological flaws such as small sample sizes, ambiguous randomization techniques, and multiple

testing (35). More well-planned research is required to offer more conclusive proof of CT and CR's effectiveness.

Supporting Caregivers of People with Dementia:

To manage care and lower societal expenditures, it is essential to support those who are caring for individuals with dementia. Numerous interventions have demonstrated efficacy in enhancing the well-being of caregivers and postponing the institutionalization of individuals receiving care. These consist of cognitive behavioral therapy, occupational therapy, and psychoeducation(36). Supportive group-based therapies have been shown to have a favorable effect on caregivers' psychological morbidity (37). With features including peer engagement, professional contact, information providing, decision support, and psychological support, internet-based interventions are becoming increasingly valuable resources. These therapies have the potential to lessen caregiver burden, anxiety, and depression, despite the generally poor quality of the research. Online psychological support and tailored information seem especially helpful. All things considered(36), helping caregivers through a variety of interventions can enhance both their own and the dementia patient's well-being while possibly lowering dependency on official care systems.

Future Directions and Research

Elaborate on the emerging trends and gaps in dementia research, including the focus on midlife, genetic risk factors, neuronal resilience, drug-target validation, clinical trial approaches, geographical and diversity gaps, life-course and multi-domain approaches, and the use of big data.

(1) Search extensively for contemporary research that highlights midlife as a crucial time for the development of early Alzheimer's disease pathology, paying particular attention to the structural and cognitive alterations in the brain that have been found..(38)

(2) Examine the present status of studies on the conversion of genetic risk factors for dementia into biological processes and possible targets for treatment.

(3) Examine the most recent research on neuronal resilience in relation to dementia, including its contributing causes and potential applications in therapy or prevention.



(4) Examine current developments and ongoing difficulties in drug-target validation for dementia, taking into account both new strategies and the causes of previous failures.

(5) Examine cutting-edge and enhanced techniques being used in dementia clinical trials, such as biomarker enrichment, adaptive designs, and novel outcomes. (39)

(6) Recognize and evaluate the lack of diversity and regional gaps in the present dementia research, and investigate efforts to close these gaps.

(7) Look into research that use multi-domain and life-course approaches to comprehend the intricate interactions between variables affecting dementia risk and to guide population-level therapies. (40)

(8) Examine the application of big data in dementia research, detailing its potential for improving prevention, prediction, and personalized treatment, while also outlining the technical, ethical, and regulatory hurdles that need to be overcome. (41)

New Diagnostic and Therapeutic Approaches for Dementia: Future Directions"

Considerable progress has been made in diagnosing and treating Alzheimer's disease (AD) and other dementias, according to recent studies. The pathological hallmarks of AD, tau tangles, The microtubule-associated protein tau lies at the heart of the tau hypothesis of Alzheimer's dementia (AD). In neuron axons, tau often stabilizes microtubules. Neurofibrillary tangles (NFTs) and microtubule breakdown are caused by unchecked tau phosphorylation in AD. Despite being essential to the pathophysiology of AD, the tau hypothesis is intimately related to the amyloid hypothesis and cannot fully account for all symptoms. According to recent studies, tau pathology may be triggered by amyloid-beta aggregation. Tau aggregates may be targets for early diagnosis and treatment. The goals of current treatment approaches are to stabilize microtubules, enhance tau clearance, or prevent tau phosphorylation or aggregation and amyloid-beta (A β) plaques, are the focus of current methods (42). While treatment interventions investigate anti-amyloid and anti-tau techniques, novel diagnostic tools strive for early diagnosis (43). Despite advancements, there are still obstacles in the way of creating viable biomarkers for early diagnosis and disease-modifying treatments. Current drugs do not stop the progression of the disease, although they do provide some symptomatic

relief. To create more thorough diagnostic and treatment methods, future directions may involve merging several disease pathways. Innovative treatments are becoming more and more necessary as the population ages. To develop drugs with disease-modifying qualities, ongoing clinical research focuses on addressing the underlying pathogenic pathways(44).

Addressing the Global Impact of Dementia:

One major worldwide health concern is dementia, which has:

- 46.8 million cases globally in 2015

-\$818 billion in expenses

- 131.5 million cases are expected to occur by 2050(45)

Global Reaction

1. More than 20 countries have national dementia policy.

2. Research and reports from the World Health Organization (WHO)

3. G8 gatherings to talk about dementia; a thorough action plan developed by an international committee (46)

Suggestions for an Action Plan

1. Improving healthcare systems: To better care for individuals with dementia, healthcare infrastructure should be strengthened.

2. Increasing research funding: To better understand dementia and create effective treatments, approximately 1% of annual illness expenses should be allocated to research.

3. Implementing risk reduction strategies: Putting strategies in place to lower the risk of dementia, such as controlling chronic diseases and encouraging healthy lifestyles(47).

4. Building a competent workforce: Educating medical personnel to offer dementia patients excellent care.

Advancements and Difficulties

1. Despite the advancements, more work must be done to combat the escalating dementia crisis:

2. More money is needed to support healthcare services and research.



3. To give dementia patients better treatment, healthcare systems must be changed (46).

4. Greater awareness and understanding of dementia are necessary to reduce stigma and promote supportive communities.

Conclusion

A complicated and progressive illness, dementia has a big influence on people, families, and healthcare systems. Early diagnosis, efficient management, and supportive care techniques are crucial for enhancing the quality of life for individuals impacted by dementia, as its prevalence is steadily increasing worldwide. Research advances highlight the significance of lifestyle changes, medical interventions, and community support, offering promise for improved treatments and possible preventive measures. In order to address dementia and create a more accepting and caring environment for those who live with the illness, healthcare professionals, caregivers, legislators, and society at large must work together.

REFERENCES

- Varghese, S. (2018). Dementia prevalence. *The British journal of psychiatry : the journal of mental science*, 186, 542 .
- Reitz, C., Brayne, C., & Mayeux, R.P. (2011). Epidemiology of Alzheimer disease. *Nature Reviews Neurology*, 7, 137-152.
- Garre-Olmo, J. (2018). [Epidemiology of Alzheimer's disease and other dementias]. *Revista de neurologia*, 66 11, 377-386 .
- Flier, W.M., & Scheltens, P. (2005). Epidemiology and risk factors of dementia. *Journal of Neurology, Neurosurgery & Psychiatry*, 76, v2 - v7.
- Javaid, S.F., Giebel, C.M., Khan, M.A., & Hashim, M.J. (2021). Epidemiology of Alzheimer's disease and other dementias: rising global burden and forecasted trends. *F1000Research*, 10, 425.
- Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W.S., & Ferri, C.P. (2013). The global prevalence of dementia: A systematic review and metaanalysis. *Alzheimer's & Dementia*, 9, 63-75.e2.
- Wortmann, M. (2014). NEW GLOBAL PREVALENCE DATA ON DEMENTIA. *Alzheimer's & Dementia*, 10.
- Garand, L., Buckwalter, K.C., & Hall, G.R. (2000). THE BIOLOGICAL BASIS OF BEHAVIORAL SYMPTOMS IN DEMENTIA. *Issues in Mental Health Nursing*, 21, 107 - 91.
- Sin Chin, K. (2023). Pathophysiology of dementia. *Australian journal of general practice*, 52 8, 516-521 .
- Anand, R., Kaushal, A., Wani, W.Y., & Gill, K.D. (2011). Road to Alzheimer's Disease: The Pathomechanism Underlying. *Pathobiology*, 79, 55 - 71.
- Sanabria-Castro, A., Alvarado-Echeverría, I., & Monge-Bonilla, C. (2017). Molecular Pathogenesis of Alzheimer's Disease: An Update. *Annals of Neurosciences*, 24, 46 - 54.
- Fillit, H.M., Nash, D.T., Rundek, T., & Zuckerman, A.L. (2008). Cardiovascular risk factors and dementia. *The American journal of geriatric pharmacotherapy*, 6 2, 100-18 .
- Bellou, V., Belbasis, L., Tzoulaki, I., Middleton, L.T., Ioannidis, J.P., & Evangelou, E. (2017). Systematic evaluation of the associations between environmental risk factors and dementia: An umbrella review of systematic reviews and meta-analyses. *Alzheimer's & Dementia*, 13, 406-418.
- Killin, L.O., Starr, J.M., Shiue, I., & Russ, T.C. (2016). Environmental risk factors for dementia: a systematic review. *BMC Geriatrics*, 16.
- Nacmias, B., Piaceri, I., Bagnoli, S., Tedde, A., Piacentini, S., & Sorbi, S. (2014). Genetics of Alzheimer's Disease and Frontotemporal Dementia. *Current molecular medicine*, 14 8, 993-1000 .
- Loy, C.T., Schofield, P., Turner, A., & Kwok, J. (2013). The Genetics of Dementia.
- Fenoglio, C., Scarpini, E., Serpente, M., & Galimberti, D. (2018). Role of Genetics and Epigenetics in the Pathogenesis of Alzheimer's Disease and Frontotemporal Dementia. *Journal of Alzheimer's Disease*, 62, 913 - 932.
- Boller, F., Verny, M., Hugonot-Diener, L., & Saxton, J.A. (2002). Clinical features and assessment of severe dementia. A review. *European journal of neurology*, 9 2, 125-36 .



19. Dickerson, B.C., Sperling, R.A., Hyman, B.T., Albert, M.S., & Blacker, D. (2007). Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment. *Archives of general psychiatry*, 64 12, 1443-50 .
20. João, M., Sara, C., Cláudia, P., Pedro, O., & Ricardo, T. (2022). Prognostic Value of Neuropsychological Profile in the Progression from Mild Cognitive Impairment to Dementia: A Retrospective Study. *Annals of Cognitive Science*.
21. Lam, K., Chan, W.S., Luk, J.K., Leung, A.Y., Luk, J., & Leung, A. (2019). Assessment and diagnosis of dementia: a review for primary healthcare professionals. *Hong Kong medical journal = Xianggang yi xue za zhi*, 25 6.
22. Turner, R.S., Stubbs, T., Davies, D.A., & Albeni, B.C. (2020). Potential New Approaches for Diagnosis of Alzheimer's Disease and Related Dementias. *Frontiers in Neurology*, 11.
23. Galasko, D.R. (2013). The Diagnostic Evaluation of a Patient With Dementia. *CONTINUUM: Lifelong Learning in Neurology*, 19, 397-410.
24. Slavin, M.J., Brodaty, H., & Sachdev, P.S. (2013). Challenges of diagnosing dementia in the oldest old population. *The journals of gerontology. Series A, Biological sciences and medical sciences*, 68 9, 1103-11 .
25. Kaye, J.A. (1998). Diagnostic challenges in dementia. *Neurology*, 51, S45 - S52.
26. Cedazo-Mínguez, A., & Winblad, B. (2010). Biomarkers for Alzheimer's disease and other forms of dementia: Clinical needs, limitations and future aspects. *Experimental Gerontology*, 45, 5-14.
27. Wilbur, J. (2023). Dementia: Dementia Types. *FP essentials*, 534, 7-11 .
28. Shaik, S.S., & Varma, A.R. (2012). Differentiating the dementias: a neurological approach. *Progress in Neurology and Psychiatry*, 16.
29. Caramelli, P., & Barbosa, M.T. (2002). Como diagnosticar as quatro causas mais frequentes de demência. *Revista Brasileira de Psiquiatria*, 24, 7-10.
30. Almeida, O.P. (2006). Dementia: What is it All About? *The Neuroradiology Journal*, 19, 433 - 440.
31. Douglas, S., James, I.A., & Ballard, C. (2004). Non-pharmacological interventions in dementia. *Advances in Psychiatric Treatment*, 10, 171-177.
32. Dyer, S.M., Harrison, S.L., Laver, K.E., Whitehead, C.H., & Crotty, M. (2017). An overview of systematic reviews of pharmacological and non-pharmacological interventions for the treatment of behavioral and psychological symptoms of dementia. *International Psychogeriatrics*, 30, 295 - 309.
33. Bahar-Fuchs, A., Clare, L., & Woods, B. (2013). Cognitive training and cognitive rehabilitation for persons with mild to moderate dementia of the Alzheimer's or vascular type: a review. *Alzheimer's Research & Therapy*, 5, 35 - 35.
34. Kallio, E., Öhman, H., Kautiainen, H., Hietanen, M., & Pitkälä, K.H. (2017). Cognitive Training Interventions for Patients with Alzheimer's Disease: A Systematic Review. *Journal of Alzheimer's disease : JAD*, 56 4, 1349-1372 .
35. Clare, L., & Woods, R.T. (2004). Cognitive training and cognitive rehabilitation for people with early-stage Alzheimer's disease: A review. *Neuropsychological Rehabilitation*, 14, 385 - 401.
36. Vandepitte, S., Van Den Noortgate, N., Putman, K., Verhaeghe, S., Faes, K., & Annemans, L. (2016). Effectiveness of Supporting Informal Caregivers of People with Dementia: A Systematic Review of Randomized and Non-Randomized Controlled Trials. *Journal of Alzheimer's disease : JAD*, 52 3, 929-65 .
37. Hopwood, J., Walker, N., McDonagh, L.K., Rait, G., Walters, K.R., Iliffe, S., Ross, J., & Davies, N. (2018). Internet-Based Interventions Aimed at Supporting Family Caregivers of People With Dementia: Systematic Review. *Journal of Medical Internet Research*, 20.
38. Mauricio, R., Benn, C.L., Davis, J.B., Dawson, G., Dawson, L.A., Evans, A.R., Fox, N.C.,
39. Irwin, K., Sexton, C.E., Daniel, T., Lawlor, B.A., & Naci, L. (2018). Healthy Aging and Dementia: Two Roads Diverging in Midlife? *Frontiers in Aging Neuroscience*, 10.
40. Gallacher, J.E., Hutton, M.L., Isaac, J.T., Jones, D., Jones, L., Lalli, G., Libri, V., Lovestone, S., Moody, C., Noble, W., Perry, H., Pickett, J.A., Reynolds, D.S., Ritchie, C.W., Rohrer, J.D.,



- Routledge, C.A., Rowe, J.B., Snyder, H.M., Spires-Jones, T.L., Swartz, J.E., Truyen, L., & Whiting, P.J. (2019). Tackling gaps in developing life-changing treatments for dementia. *Alzheimer's & Dementia : Translational Research & Clinical Interventions*, 5, 241 - 253.
41. Anstey, K.J., Peters, R., Zheng, L., Barnes, D.E., Brayne, C., Brodaty, H., Chalmers, J., Clare, L., Dixon, R.A., Dodge, H.H., Lautenschlager, N.T., Middleton, L.E., Qiu, C., Rees, G., Shahar, S., & Yaffe, K. (2020). Future Directions for Dementia Risk Reduction and Prevention Research: An International Research Network on Dementia Prevention Consensus. *Journal of Alzheimer's Disease*, 78, 3 - 12.
42. Rajasekhar, K., & Govindaraju, T. (2018). Current progress, challenges and future prospects of diagnostic and therapeutic interventions in Alzheimer's disease. *RSC Advances*, 8, 23780 - 23804.
43. Tanwir, S.E., & Kumar, A. (2019). Recent Advances in the Quest for Treatment and Management of Alzheimer and Other Dementia. *Open Journal of Medicinal Chemistry*.
44. Klafki, H.W., Staufenbiel, M., Kornhuber, J., & Wiltfang, J. (2006). Therapeutic approaches to Alzheimer's disease. *Brain : a journal of neurology*, 129 Pt 11, 2840-55 .
45. Prince, M.J., Wimo, A., Guerchet, M., Ali, G., Wu, Y., & Prina, M.A. (2015). World Alzheimer Report 2015 - The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends.
46. Wortmann, M. (2016). GLOBAL DEMENTIA POLICY OVERVIEW. *Alzheimer's & Dementia*, 12, P995-P996.
47. Chertkow, H., Aging, R.E., & Dementia, I.I. (2018). An Action Plan to Face the Challenge of Dementia: INTERNATIONAL STATEMENT ON DEMENTIA from IAP for Health. *The Journal of Prevention of Alzheimer's Disease*, 5, 207-212.